- لايفيرا أوميكس Read more »
Lifera Omics Appoints Prof. Fowzan Alkuraya, a Renowned Genomics Expert as Chief Medical and Genomic Officer
- Lifera, a biopharma company wholly owned by the Public Investment Fund (PIF), launched in 2023, is scaling up its subsidiary Lifera Omics and developing a team of leading Saudi and global talent to fulfil its [...] Read more »
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top–line results of the SYCAMORE trial, a [...] Read more »
Brains Bioceutical Deve Obter o Primeiro Certificado CEP do Mundo para Canabinóides, do European Directorate de Qualidade de Medicamentos e Cuidados de Saúde
SANDWICH, Reino Unido, Aug. 22, 2024 (GLOBE NEWSWIRE) — A Brains Bioceutical Corp. (BBC) alcançou um marco inovador ao fazer um dos primeiros pedidos de CEP (Certificação de Adequação) do mundo para [...] Read more »
Brains Bioceutical s’apprête à obtenir l’une des premières certifications CEP pour le cannabidiol au monde auprès de la Direction européenne de la qualité du médicament et soins de santé
SANDWICH, Royaume–Uni, 23 août 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (BBC) a franchi une étape décisive en soumettant l’une des premières demandes de CEP (Certification de [...] Read more »
Brains Bioceutical steht kurz vor Erhalt einer der weltweit ersten CEP-Zertifizierungen für Cannabidiol vom Europäischen Direktorat für die Qualität von Arzneimitteln und Gesundheitsfürsorge
SANDWICH, Vereinigtes Königreich, Aug. 23, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (BBC) hat einen bahnbrechenden Meilenstein erreicht, indem es einen der weltweit ersten CEP–Anträge (Eignungszertifikat) [...] Read more »
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare
SANDWICH, United Kingdom, Aug. 22, 2024 (GLOBE NEWSWIRE) — Brains Bioceutical Corp. (BBC) has achieved a groundbreaking milestone by submitting one of the world’s first CEP (Certification of Suitability) application for its [...] Read more »
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Infectious Disease Expert Kelly Warfield Named Sabin’s New R&D President
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield
WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) — Virologist and vaccine development leader Kelly Warfield [...] Read more »
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
- Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a leading [...] Read more »
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting – Key SABRE Update Also Expected
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today [...] Read more »
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month.
Read more »
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology–based therapies, today [...] Read more »